MedTrace Logo

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

NCT01327911 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-11-22

No results posted yet for this study

Summary

This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.

Conditions

  • Idiopathic Juxtafoveal Telangiectasia

Interventions

BIOLOGICAL

NT-501 implant

Ciliary neurotrophic factor (CNTF) implant

Sponsors & Collaborators

  • The Lowy Medical Research Institute Limited

    collaborator OTHER

  • Neurotech Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Weng Tao · Neurotech USA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327911 on ClinicalTrials.gov